Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.49 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.49 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.49 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.45 |
| ▸ | MET | P08581 | 3/20 | 0.45 |
| ▸ | ROS1 | P08922 | 2/20 | 0.45 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
| ▸ | INSR | P06213 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.36 |
| ▸ | CDK2 | P24941 | 4/20 | 0.36 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | CCNK | O75909 | 2/20 | 0.35 |
| ▸ | CCND3 | P30281 | 2/20 | 0.35 |
| ▸ | CDK9 | P50750 | 2/20 | 0.35 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.35 |
| ▸ | HPGDS | O60760 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22858432 | 0.97 | MAPK8 (0.46) | MAPK8MAPK9MAPK10ALKMET | |
| SCHEMBL22858558 | 0.89 | MAPK8 (0.40) | MAPK8MAPK9MAPK10ALKMET | |
| SCHEMBL29508923 | 0.89 | MAPK8 (0.40) | MAPK8MAPK9MAPK10ALKMET | |
| SCHEMBL22858604 | 0.86 | MAPK8 (0.38) | MAPK8MAPK9MAPK10ALKMET | |
| SCHEMBL22858593 | 0.83 | EGFR (0.43) | MAPK8MAPK9MAPK10ALKROS1 | |
| SCHEMBL22858537 | 0.81 | CCNA2 (0.47) | CNR2SLC2A1CCNA2CDK2CCNK | |
| SCHEMBL22858418 | 0.80 | CCNA2 (0.48) | CNR2SLC2A1CCNA2CDK2CCNK | |
| SCHEMBL22858417 | 0.80 | SLC2A1 (0.64) | MAPK8MAPK9MAPK10ALKSLC2A1 | |
| SCHEMBL29509068 | 0.80 | SLC2A1 (0.64) | MAPK8MAPK9MAPK10ALKSLC2A1 | |
| SCHEMBL22858453 | 0.76 | ALK (0.48) | MAPK8MAPK9MAPK10ALKMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4274567-A1 | FORMS AND FORMULATIONS OF A TYROSINE KINASE NON-RECEPTOR 1 (TNK1) INHIBITOR | Sumitomo Pharma Oncology, Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| CN-116829143-A | Forms and formulations of non-receptor tyrosine kinase 1 (TNK 1) inhibitors | 住友制药肿瘤公司 | 2023-09-29 | — | — | CN | disclosed |
| US-11529350-B2 | Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof | SUMITOMO PHARMA ONCOLOGY, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| WO-2022150801-A1 | FORMS AND FORMULATIONS OF A TYROSINE KINASE NON-RECEPTOR 1 (TNK1) INHIBITOR | SUMITOMO PHARMA ONCOLOGY, INC. (US) | 2022-07-14 | — | — | WO | disclosed |
| WO-2022150801-A1 | FORMS AND FORMULATIONS OF A TYROSINE KINASE NON-RECEPTOR 1 (TNK1) INHIBITOR | SUMITOMO PHARMA ONCOLOGY, INC. (US) | 2022-07-14 | — | — | WO | disclosed |
| EP-3994132-A1 | TYROSINE KINASE NON-RECEPTOR 1 (TNK1) INHIBITORS AND USES THEREOF | Sumitomo Dainippon Pharma Oncology, Inc. (US) | 2022-05-11 | — | — | EP | disclosed |
| CN-114302878-A | Tyrosine kinase non-receptor 1(TNK1) inhibitors and uses thereof | 大日本住友制药肿瘤公司 | 2022-04-08 | — | — | CN | disclosed |
| US-20210000825-A1 | Tyrosine Kinase Non-Receptor 1 (TNK1) Inhibitors and Uses Thereof | SUMITOMO PHARMA ONCOLOGY, INC. | 2021-01-07 | — | — | US | disclosed |
| WO-2021003417-A1 | TYROSINE KINASE NON-RECEPTOR 1 (TNK1) INHIBITORS AND USES THEREOF | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2021-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210000825-A1 | Tyrosine Kinase Non-Receptor 1 (TNK1) Inhibitors and Uses Thereof | TNK1, TNNI3K, TYK2 | MAPK8 340/4885MAPK9 273/4885MAPK10 302/4885 |
| US-11529350-B2 | Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof | TNK1, TNNI3K, TYK2 | MAPK8 340/4885MAPK9 273/4885MAPK10 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.